Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy

被引:93
作者
Devillier, Raynier [1 ]
Coso, Diane [1 ]
Castagna, Luca [1 ,2 ]
Rossi, Isabelle Brenot [3 ]
Anastasia, Antonella [2 ]
Chiti, Arturo [4 ]
Ivanov, Vadim [1 ]
Schiano, Jean Marc [1 ]
Santoro, Armando [2 ]
Chabannon, Christian [1 ,5 ,6 ]
Balzarotti, Monica [2 ]
Blaise, Didier [1 ,5 ,6 ]
Bouabdallah, Reda [1 ]
机构
[1] Inst J Paoli I Calmettes, Dept Hematol, Transplantat & Cell Therapy Program, F-13009 Marseille, France
[2] Ist Clin Humanitas, Humanitas Canc Ctr, Hematol Unit, Milan, Italy
[3] Inst J Paoli I Calmettes, Dept Nucl Med, F-13009 Marseille, France
[4] Ist Clin Humanitas, Humanitas Canc Ctr, Nucl Med Unit, Milan, Italy
[5] Inst J Paoli I Calmettes, INSERM, CBT 510, Ctr Invest Clin Biotherapie, F-13009 Marseille, France
[6] Univ Aix Marseille, Fac Med, Inst J Paoli I Calmettes, Marseille, France
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2012年 / 97卷 / 07期
关键词
Hodgkin's lymphoma; PET; outcome; relapsed refractory; ASCT; HIGH-DOSE CHEMOTHERAPY; PROGNOSTIC-FACTORS; FDG-PET; DISEASE; MULTICENTER; FAILURE; SCORE;
D O I
10.3324/haematol.2011.056051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for relapsed and/or refractory Hodgkin's lymphoma although half of patients relapse after transplantation. Predictive factors, such as relapse within 12 months, Ann-Arbor stage at relapse, and relapse in previously irradiated fields are classically used to identify patients with poor outcome. Recently, 18-fluorodeoxyglucose positron emission tomography has emerged as a new method for providing information to predict outcome. The aim of this study was to confirm the predictive value of positron emission tomography status after salvage therapy and to compare single versus tandem autologous stem cell transplantation in patients with relapsed and/or refractory Hodgkin's lymphoma. Design and Methods We report a series of 111 consecutive patients with treatment-sensitive relapsed and/or treatment-refractory Hodgkin's lymphoma who achieved complete (positron emission tomography-negative group) or partial remission (positron emission tomography-positive group) at positron emission tomography evaluation after salvage chemotherapy and who underwent single or tandem autologous stem cell transplantation. Results Five-year overall and progression-free survival rates were 81% and 64%, respectively. There were significant differences in 5-year progression-free survival (79% versus 23%; P<0.001) and 5-year overall survival (90% versus 55%, P=0.001) between the positron emission tomography-negative and -positive groups, respectively. A complete response, as determined by positron emission tomography evaluation, after salvage therapy predicted significantly better 5-year overall survival rates in both intermediate (91% versus 50%; P=0.029) and unfavorable (89% versus 58%; P=0.026) risk subgroup analyses. In the positron emission tomography-positive subgroup, tandem transplantation improved 5-year progression-free survival from 0% (in the single transplantation group) to 43% (P=0.034). Multivariate analysis showed that positron emission tomography status (hazard ratio: 5.26 [2.57-10.73]) and tandem transplantation (hazard ratio: 0.39 [0.19-0.78]) but not risk factors at relapse (hazard ratio: 1.77 [0.80-3.92]) significantly influenced progression-free survival, while only tomography status significantly influenced overall survival (hazard ratio: 4.03 [1.38-11.75]). Conclusions In patients with relapsed/refractory Hodgkin's lymphoma responding to prior salvage therapy, positron emission tomography response at time of autologous stem cell transplantation favorably influences outcome and enables identification of patients requiring single or tandem transplantation.
引用
收藏
页码:1073 / 1079
页数:7
相关论文
共 30 条
[1]   Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry [J].
Brice, P ;
Bouabdallah, R ;
Moreau, P ;
Divine, M ;
Andre, M ;
Aoudjane, M ;
Fleury, J ;
Anglaret, B ;
Baruchel, A ;
Sensebe, L ;
Colombat, P .
BONE MARROW TRANSPLANTATION, 1997, 20 (01) :21-26
[2]   Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD) [J].
Brice, P ;
Divine, M ;
Simon, D ;
Coiffier, B ;
Leblond, V ;
Simon, M ;
Voilat, L ;
Devidas, A ;
Morschhauser, F ;
Rohrlich, P ;
André, M ;
Lepage, E ;
Ferme, C .
ANNALS OF ONCOLOGY, 1999, 10 (12) :1485-1488
[3]   Long-term follow-up of Hodgkin's disease trial [J].
Canellos, GP ;
Niedzwiecki, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (18) :1417-1418
[4]   Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma [J].
Carella, AM ;
Cavaliere, M ;
Lerma, E ;
Ferrara, R ;
Tedeschi, L ;
Romanelli, A ;
Vinci, M ;
Pinotti, G ;
Lambelet, P ;
Loni, C ;
Verdiani, S ;
De Stefano, F ;
Valbonesi, M ;
Corsetti, MT .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) :3918-3924
[5]   Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study [J].
Castagna, Luca ;
Magagnoli, Massimo ;
Balzarotti, Monica ;
Sarina, Barbara ;
Siracusano, Licia ;
Nozza, Andrea ;
Todisco, Elisabetta ;
Bramanti, Stefania ;
Mazza, Rita ;
Russo, Filippo ;
Timofeeva, Inna ;
Santoro, Armando .
AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (02) :122-127
[6]   Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma [J].
Castagna, Luca ;
Sarina, Barbara ;
Todisco, Elisabetta ;
Magagnoli, Massimo ;
Balzarotti, Monica ;
Bramanti, Stefania ;
Mazza, Rita ;
Anastasia, Antonella ;
Bacigalupo, Andrea ;
Aversa, Franco ;
Soligo, Davide ;
Giordano, Laura ;
Santoro, Armando .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (04) :432-438
[7]   Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy [J].
Castagna, Luca ;
Bramanti, Stefania ;
Balzarotti, Monica ;
Sarina, Barbara ;
Todisco, Elisabetta ;
Anastasia, Antonella ;
Magagnoli, Massimo ;
Mazza, Rita ;
Nozza, Andrea ;
Giordano, Laura ;
Rodari, Marcello ;
Rinifilo, Eva ;
Chiti, Arturo ;
Santoro, Armando .
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (03) :369-372
[8]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[9]  
COX DR, 1972, J R STAT SOC B, V34, P187
[10]   Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study [J].
Engert, Andreas ;
Diehl, Volker ;
Franklin, Jeremy ;
Lohri, Andreas ;
Doerken, Bernd ;
Ludwig, Wolf-Dieter ;
Koch, Peter ;
Haenel, Mathias ;
Pfreundschuh, Michael ;
Wilhelm, Martin ;
Truemper, Lorenz ;
Aulitzky, Walter-Erich ;
Bentz, Martin ;
Rummel, Mathias ;
Sezer, Orhan ;
Mueller-Hermelink, Hans-Konrad ;
Hasenclever, Dirk ;
Loeffler, Markus .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4548-4554